Antimitochondrial antibodies
EstablishedAMA is the hallmark diagnostic antibody for primary biliary cholangitis, a chronic liver disease.
This antibody is the classic marker for primary biliary cholangitis, a liver disease. A negative result on a basic test doesn't fully rule it out — more sensitive tests, including two other specific antibodies, can often still find evidence of the disease.
Antimitochondrial antibodies (AMA) target mitochondrial proteins, most specifically the PDC-E2 complex (AMA-M2 subtype), and are the hallmark serologic marker of primary biliary cholangitis (PBC), a chronic autoimmune liver disease.
AMA positivity is highly specific for PBC; AASLD diagnostic criteria require meeting 2 of 3 findings (elevated alkaline phosphatase, AMA or PBC-specific ANA positivity, or compatible liver histology) rather than AMA alone.
Measured via indirect immunofluorescence or more sensitive ELISA/immunoblot; up to 20% of PBC patients appear AMA-negative on standard immunofluorescence, but more sensitive testing combined with PBC-specific antibodies (anti-sp100, anti-gp210) reclassifies most of these as truly AMA-positive, shrinking genuinely AMA-negative PBC to under 5%.
Confirmed PBC guides initiation of ursodeoxycholic acid as first-line therapy; the diagnostic algorithm for "AMA-negative" cases includes anti-sp100/anti-gp210 testing before concluding a patient lacks the antibody.
Highly specific for PBC; apparent AMA-negative cases often resolve as positive with more sensitive testing.
- AASLD. (2021). Primary Biliary Cholangitis Practice Guidance.
- Al-Handola, R., et al. (2023). Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: A Retrospective Diagnosis. Cureus.